Business
Bio-Thera Solutions Announces First Patient Dosed in Phase 3 Clinical Trial for BAT8006, an Antibody Drug Conjugate Targeting Folate Receptor α for the Treatment of Platinum-Resistant Ovarian Cancer
Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced that dosing has begun in a phase 3 clinical study for BAT8006, an antibody drug conjugate targeting folate receptor α for the treatment of platinum-resistant ovarian cancer. The phase 3, randomized, open-label, parallel-group clinical trial (Clinical Trial Registration Number: CTR20251345) of BAT8006 is designed to assess the efficacy o
About this update from Bio-thera Solutions, Ltd. Class A
[{"type":"text","content":"GUANGZHOU, China, June 25, 2025 /PRNewswire/ - Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced that dosing has begun in a phase 3 clinical study for BAT8006, an antibody drug conjugate targeting folate receptor α for the treatment of platinum-resistant ovarian cancer. The phase 3, randomized, open-label, parallel-group clinical trial (Clinical Trial Registration Number: CTR20251345) of BAT8006 is designed to assess the efficacy of BAT8006 versus investigator's choice of single-agent chemotherapy in patients with platinum-resistant high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer.","length":748,"tagName":"p"},{"type":"image","alt":"Bio-Thera Solutions, Ltd., a leading innovative, global biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases. (PRNewsfoto/Bio-Thera Solutions, Ltd)","displaySize":"","headline":null,"caption":"Bio-Thera Solutions, Ltd., a leading innovative, global biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases. (PRNewsfoto/Bio-Thera Solutions, Ltd)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":209,"url":"https://media.zenfs.com/en/prnewswire.com/5dcaa2a938f74c36f27e3fbb7b39275b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dzycamzHTMsuwCYxDRsNuA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM2ODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/5dcaa2a938f74c36f27e3fbb7b39275b","width":400,"height":209}},"href":"https://mma.prnewswire.com/media/2332090/3Bio_Thera_LOGO_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"At the Rapid Oral Abstract Session of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, early clinical data of BAT8006 demon...